

## June 2020

## **Statin Therapy for Patients with Diabetes**

Adults 40–75 years of age with diabetes, who do or do not have clinical atherosclerotic cardiovascular disease (ASCVD), should be started on a statin for primary and secondary prevention of ASCVD regardless of lipid status.

Medications			
One of the following medications must have been dispensed.  Note: The active ingredients are limited to oral formulations only.			
Statin medications	Lovastatin	<ul> <li>Rosuvastatin</li> </ul>	
	<ul> <li>Fluvastatin</li> </ul>	<ul> <li>Atorvastatin</li> </ul>	
	Pravastatin	<ul> <li>Pitavastatin</li> </ul>	
	Simvastatin		
Statin combination products	Atorvastatin / amlodipine	<ul> <li>Simvastatin / ezetimibe</li> </ul>	
	Atorvastatin / ezetimibe	<ul> <li>Simvastatin / niacin</li> </ul>	
	Lovastatin / niacin	<ul> <li>Simvastatin / sitagliptin</li> </ul>	
Standard exclusion(s)	Timeframe		
Patients in hospice	Any time during the measurement year		
<ul> <li>End-stage renal disease (ESRD)</li> </ul>	<ul> <li>Any time during the measurement year or the year prior to the</li> </ul>		
	measurement		

- 1) For diabetics without ASCVD, use MODERATE INTENSITY statin for primary prevention<sup>1</sup>.
- 2) For diabetics "with" ASCVD, use HIGH INTENSITY statin for secondary prevention<sup>2</sup>.
- 3) Low Intensity statins are not recommended unless unable to tolerate moderate or high intensity.

High Intensity	Moderate Intensity	Low Intensity
Daily dose lowers LDL-C on average	Daily dose lowers LDL-C on average	Daily dose lowers LDL-C on average
by ≈ ≥50%	by ≈ 30% to <50%	by <30%
Atorvastatin 40-80 mg	Atorvastatin 10-20 mg	Simvastatin 10 mg
Rosuvastatin 20-40 mg	Rosuvastatin 5-10 mg	Pravastatin 10-20 mg
	Simvastatin 20-40 mg	Lovastatin 20 mg
	Pravastatin 40-80 mg	Fluvastatin 20-40 mg
	Lovastatin 40 mg	Pitavastatin 1 mg
	Fluvastatin XL 80 mg	
	Fluvastatin 40 mg bid	
	Pitavastatin 2-4 mg	

## **References:**

- 1. Cochrane Database Syst Rev. 2013:CD004816
- 2. Diabetes Care 2006 Jun; 29(6): 1220-1226.

## \*\* Promote Statin Use in Diabetics \*\*

If you have any questions, please contact Dr. Preston Thomas, Associate Medical Director at 248-484-4980 or

Preston.Thomas@McLaren.org